The link to Clinical Connection will remain on the sidebar; under clinical trials
.
How To Use These Links:
1-The links below will take you to Clinical Connection
2. Once at the site you will be given information about the trial * see example
3. If you are interested in the trial: Scroll down to the bottom of the information to the ClinicalTrials.gov link which reads:
"If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov. "* Click on "clinical trials.com" and it will bring you to the corralating information at the .gov site.
.
Example:
.
A Drug-Drug Interaction Study Evaluating the Combination of IDX320 and IDX184 in Healthy Subjects - NCT01157104-68502 (Clinical Trial 688159)
City: Lincoln State: NE Zip Code:8502
Conditions:
Chronic Hepatitis C
Purpose:
This study is designed to evaluate the potential for a pharmacokinetic (PK) drug-drug interaction between IDX320 and IDX184 and to assess the safety and tolerability when the two drugs are administered in combination in healthy subjects.
Study summary:
Criteria:
Inclusion Criteria: To participate in the study, subjects must meet the following requirements:
City: Lincoln State: NE Zip Code:8502
Conditions:
Chronic Hepatitis C
Purpose:
This study is designed to evaluate the potential for a pharmacokinetic (PK) drug-drug interaction between IDX320 and IDX184 and to assess the safety and tolerability when the two drugs are administered in combination in healthy subjects.
Study summary:
Criteria:
Inclusion Criteria: To participate in the study, subjects must meet the following requirements:
1. Must be a healthy male or female between 19 and 65 years of age with body mass index (BMI) between 18 and 35 kg/m2.
2. Must be a non-smoker.
3. Must agree to use an acceptable double-barrier method of birth control. 4. Must provide written informed consent after the study has been fully explained.
Exclusion Criteria: Subjects are not eligible if they meet any of the following: 1. Pregnant or breastfeeding.
2. History of clinically significant diseases, as determined by the investigator.
3. Safety laboratory abnormalities at screening which are clinically significant.
4. Positive screening test for hepatitis B virus, hepatitis C virus or human immunodeficiency virus (HIV).
5. Use of chronic prescription medications within 3 months, acute prescription medications within 14 days, or systemic over-the-counter (OTC) medications within 7 days of the starting the study.
6. Current abuse of alcohol or illicit drugs, or history of alcohol or illicit drug abuse within the preceding two years.
Study is available at:
Lincoln, NE 68502 United States Primary Contact:John Sullivan-Bólyai, MD, MPH Email: clinicaltrials@idenix.com Phone: 877-433-6491
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Study is available at:
Lincoln, NE 68502 United States Primary Contact:John Sullivan-Bólyai, MD, MPH Email: clinicaltrials@idenix.com Phone: 877-433-6491
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
.
.
Conditions: Chronic Hepatitis CLocation: Lincoln, NE
A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-19139
A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-19139
Conditions: HCV InfectionLocation: Philadelphia, PA
A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-20010
A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-20010
Conditions: HCV InfectionLocation: Washington, DC
A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-32720
A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-32720
Conditions: HCV InfectionLocation: Deland, FL
A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-32809
A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-32809
Conditions: HCV InfectionLocation: Orlando, FL
A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-33169
A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-33169
Conditions: HCV InfectionLocation: Miami, FL
A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-63104
A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-63104
Conditions: HCV InfectionLocation: St. Louis, MO
A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-77030
A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-77030
Conditions: HCV InfectionLocation: Houston, TX
A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-78215
A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-78215
Conditions: HCV InfectionLocation: San Antonio, TX
A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-90630
A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-90630
Conditions: HCV InfectionLocation: Cypress, CA
A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-91950
A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-91950
Conditions: HCV InfectionLocation: National City, CA
A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-92801
A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-92801
Conditions: HCV InfectionLocation: Anaheim, CA
A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-97239
A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-97239
Conditions: HCV InfectionLocation: Portland, OR
A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-98418
A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-98418
Conditions: HCV InfectionLocation: Tacoma, WA
A Network & Dyad HIV Prevention Intervention for IDU's - 1 - NCT00218335-21231
A Network & Dyad HIV Prevention Intervention for IDU's - 1 - NCT00218335-21231
Conditions: HIV - HepatitisLocation: Baltimore, MD
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-02114
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-02114
Conditions: HIV Infections - Hepatitis C - HCV InfectionLocation: Boston, MA
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-07102
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-07102
Conditions: HIV Infections - Hepatitis C - HCV InfectionLocation: Newark, NJ
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-10021
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-10021
Conditions: HIV Infections - Hepatitis C - HCV InfectionLocation: New York, NY
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-14642
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-14642
Conditions: HIV Infections - Hepatitis C - HCV InfectionLocation: Rochester, NY
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-21093
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-21093
Conditions: HIV Infections - Hepatitis C - HCV InfectionLocation: Lutherville, MD
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-23298
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-23298
Conditions: HIV Infections - Hepatitis C - HCV InfectionLocation: Richmond, VA
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-34243
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-34243
Conditions: HIV Infections - Hepatitis C - HCV InfectionLocation: Sarasota, FL
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-45267
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-45267
Conditions: HIV Infections - Hepatitis C - HCV InfectionLocation: Cincinnati, OH
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-92103
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-92103
Conditions: HIV Infections - Hepatitis C - HCV InfectionLocation: San Diego, CA
A Phase II Study to Determine the Safety and Efficacy of Interferon-gamma in Patients With Chronic Hepatitis B - NCT00753467-91105
A Phase II Study to Determine the Safety and Efficacy of Interferon-gamma in Patients With Chronic Hepatitis B - NCT00753467-91105
Conditions: Hepatitis BLocation: Pasadena, CA
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-02114
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-02114
Conditions: Chronic Hepatitis B Virus, PediatricLocation: Boston, MA
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-02115C
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-02115C
onditions: Chronic Hepatitis B Virus, PediatricLocation: Boston, MA
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-02903
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-02903
Conditions: Chronic Hepatitis B Virus, PediatricLocation: Providence, RI
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-06106
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-06106
Conditions: Chronic Hepatitis B Virus, PediatricLocation: Hartford, CT
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-10029
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-10029
Conditions: Chronic Hepatitis B Virus, PediatricLocation: New York, NY
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-19104
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-19104
Conditions: Chronic Hepatitis B Virus, PediatricLocation: Philadelphia, PA
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-20010
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-20010
Conditions: Chronic Hepatitis B Virus, PediatricLocation: Washington, DC
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-21287
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-21287
Conditions: Chronic Hepatitis B Virus, PediatricLocation: Baltimore, MD
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-22031
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-22031
Conditions: Chronic Hepatitis B Virus, PediatricLocation: Fairfax, VA
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-28226
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-28226
Conditions: Chronic Hepatitis B Virus, PediatricLocation: Charlotte, NC
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-30322
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-30322
Conditions: Chronic Hepatitis B Virus, PediatricLocation: Atlanta, GA
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-32610
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-32610
Conditions: Chronic Hepatitis B Virus, PediatricLocation: Gainesville, FL
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-77030
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-77030
Conditions: Chronic Hepatitis B Virus, PediatricLocation: Houston, TX
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-94143
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-94143
Conditions: Chronic Hepatitis B Virus, PediatricLocation: San Francisco, CA
A Pilot Study of the Grapefruit Flavonoid Naringenin for HCV Infection - NCT01091077-02114
A Pilot Study of the Grapefruit Flavonoid Naringenin for HCV Infection - NCT01091077-02114
Conditions: Hepatitis C Virus - HCV Infection - Chronic HCV - Hepatitis CLocation: Boston, MA
A Pilot Study to Examine the Role of Nitazoxanide to Prevent Recurrence of Hepatitis C After Transplantation - NCT01074203-55905
A Pilot Study to Examine the Role of Nitazoxanide to Prevent Recurrence of Hepatitis C After Transplantation - NCT01074203-55905
Conditions: Hepatitis C RecurrenceLocation: Rochester, MN
A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C - NCT00814606-60637
A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C - NCT00814606-60637
Conditions: Hepatitis C - Hepatitis C VirusLocation: Chicago, IL
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-10016
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-10016
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: New York, NY
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-10021C
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-10021C
onditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: New York, NY
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-19141
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-19141
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Philadelphia, PA
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-21287
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-21287
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Baltimore, MD
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-23249
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-23249
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Richmond, VA
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-27599
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-27599
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Chapel Hill, NC
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-27705
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-27705
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Durham, NC
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-32803
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-32803
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Orlando, FL
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-32809
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-32809
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Orlando, FL
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-33136
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-33136
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Miami, FL
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-46202
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-46202
onditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Indianapolis, IN
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-48202
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-48202
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Detroit, MI
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-53792
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-53792
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Madison, WI
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-55114
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-55114
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: St. Paul, MN
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-60611
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-60611
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Chicago, IL
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-60612
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-60612
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Chicago, IL
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-63104
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-63104
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: St. Louis, MO
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-70112
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-70112
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: New Orleans, LA
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-70808
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-70808
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Baton Rouge, LA
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-75203A
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-75203A
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Dallas, TX
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-75203B
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-75203B
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Dallas, TX
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-77030
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-77030
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Houston, TX
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-78215
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-78215
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: San Antonio, TX
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-80045
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-80045
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Aurora, CO
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-84132
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-84132
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Salt Lake City, UT
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-85054
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-85054
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Phoenix, AZ
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-90048
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-90048
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Los Angeles, CA
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-92037
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-92037
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: La Jolla, CA
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-92801
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-92801
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Anaheim, CA
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-98101
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-98101
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Seattle, WA
A Randomized Trial of Vaccine Adherence in Young Injection Drug Users - 1 - NCT00244374-94143
A Randomized Trial of Vaccine Adherence in Young Injection Drug Users - 1 - NCT00244374-94143
Conditions: Adherence - Community Outreach - HIV Risk Behaviors - Hepatitis A Vaccines - Hepatitis B Vaccines - Hepatitis C - Needle-Exchange Programs - Substance Abuse, IntravenousLocation: San Francisco, CA
A Randomized, Controlled Trial of Fluvastatin Added to Pegylated Interferon and Ribavirin (PI+R) Versus PI+R Alone for Treatment of Chronic Hepatitis C Not Previously Treated - NCT00487318-73104
A Randomized, Controlled Trial of Fluvastatin Added to Pegylated Interferon and Ribavirin (PI+R) Versus PI+R Alone for Treatment of Chronic Hepatitis C Not Previously Treated - NCT00487318-73104
Conditions: Chronic Hepatitis CLocation: OKlahoma City, OK
A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection - NCT01080222-
A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection - NCT01080222-
Conditions: Chronic Hepatitis C Virus InfectionLocation: Falls Church, VA
A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-19141Conditions: Chronic Hepatitis C Virus Genotype 1Location: Philadelphia, PA
A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-20010Conditions: Chronic Hepatitis C Virus Genotype 1Location: Washington, DC
A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-20707
A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-19141Conditions: Chronic Hepatitis C Virus Genotype 1Location: Philadelphia, PA
A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-20010Conditions: Chronic Hepatitis C Virus Genotype 1Location: Washington, DC
A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-20707
Conditions: Chronic Hepatitis C Virus Genotype 1Location: Laurel, MD
A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-23602
A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-23602
Conditions: Chronic Hepatitis C Virus Genotype 1Location: Newport News, VA
A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-30060
A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-30060
Conditions: Chronic Hepatitis C Virus Genotype 1Location: Mareitta, GA
A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-32803
A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-32803
Conditions: Chronic Hepatitis C Virus Genotype 1Location: Orlando, FL
A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-33319
A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-33319
Conditions: Chronic Hepatitis C Virus Genotype 1Location: Tamarac, FL
A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-34243
A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-34243
Conditions: Chronic Hepatitis C Virus Genotype 1Location: Sarasota, FL
A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-75246
A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-75246
Conditions: Chronic Hepatitis C Virus Genotype 1Location: Dallas, TX
A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-92105
A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-92105
Conditions: Chronic Hepatitis C Virus Genotype 1Location: San Diego, CA
A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-92118
A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-92118
Conditions: Chronic Hepatitis C Virus Genotype 1Location: Coronado, CA
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-02114
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-02114
Conditions: Hepatitis C, ChronicLocation: Boston, MA
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-07601
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-07601
Conditions: Hepatitis C, ChronicLocation: Hackensack, NJ
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-08234
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-08234
Conditions: Hepatitis C, ChronicLocation: Egg Harbour Township, NJ
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-10016
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-10016
Conditions: Hepatitis C, ChronicLocation: New York, NY
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-13210
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-13210
Conditions: Hepatitis C, ChronicLocation: Syracuse, NY
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-22031
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-22031
Conditions: Hepatitis C, ChronicLocation: Fairfax, VA
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-22908
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-22908
Conditions: Hepatitis C, ChronicLocation: Charlottesville, VA
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-23249
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-23249
Conditions: Hepatitis C, ChronicLocation: Richmond, VA
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-27103
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-27103
Conditions: Hepatitis C, ChronicLocation: Winston-salem, NC
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-27599
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-27599
Conditions: Hepatitis C, ChronicLocation: Chapel Hill, NC
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-28801
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-28801
Conditions: Hepatitis C, ChronicLocation: Asheville, NC
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-30060
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-30060
Conditions: Hepatitis C, ChronicLocation: Marietta, GA
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-30308
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-30308
Conditions: Hepatitis C, ChronicLocation: Atlanta, GA
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-32256
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-32256
Conditions: Hepatitis C, ChronicLocation: Jacksonville, FL
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-32803
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-32803
Conditions: Hepatitis C, ChronicLocation: Orlando, FL
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-35294
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-35294
Conditions: Hepatitis C, ChronicLocation: Birmingham, AL
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-37660
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-37660
Conditions: Hepatitis C, ChronicLocation: Kingsport, TN
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-38801
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-38801
Conditions: Hepatitis C, ChronicLocation: Tupelo, MS
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-63104
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-63104
Conditions: Hepatitis C, ChronicLocation: St Louis, MO
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-63110
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-63110
Conditions: Hepatitis C, ChronicLocation: St Louis, MO
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-70520
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-70520
Conditions: Hepatitis C, ChronicLocation: Opelousas, LA
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-70890
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-70890
Conditions: Hepatitis C, ChronicLocation: Baton Rouge, LA
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-73112
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-73112
Conditions: Hepatitis C, ChronicLocation: Oklahoma City, OK
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-78234
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-78234
Conditions: Hepatitis C, ChronicLocation: Fort Sam Houston, TX
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-80045
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-80045
Conditions: Hepatitis C, ChronicLocation: Aurora, CO
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-84132
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-84132
Conditions: Hepatitis C, ChronicLocation: Salt Lake City, UT
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-87131
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-87131
Conditions: Hepatitis C, ChronicLocation: Albuquerque, NM
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-90048
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-90048
Conditions: Hepatitis C, ChronicLocation: Los Angeles, CA
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-90057
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-90057
Conditions: Hepatitis C, ChronicLocation: Los Angeles, CA
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-90505
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-90505
Conditions: Hepatitis C, ChronicLocation: Torrance, CA
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-90822
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-90822
Conditions: Hepatitis C, ChronicLocation: Long Beach, CA
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-92037
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-92037
Conditions: Hepatitis C, ChronicLocation: La Jolla, CA
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-92103
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-92103
Conditions: Hepatitis C, ChronicLocation: San Diego, CA
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-93534
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-93534
Conditions: Hepatitis C, ChronicLocation: Lancaster, CA
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-95816
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-95816
Conditions: Hepatitis C, ChronicLocation: Sacramento, CA
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-95817
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-95817
Conditions: Hepatitis C, ChronicLocation: Sacramento, CA
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-96813
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-96813
Conditions: Hepatitis C, ChronicLocation: Honolulu, HI
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-97239
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-97239
Conditions: Hepatitis C, ChronicLocation: Portland, OR
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-02905
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-02905
Conditions: Hepatitis C, ChronicLocation: Providence, RI
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-10021
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-10021
Conditions: Hepatitis C, ChronicLocation: New York, NY
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-10468
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-10468
Conditions: Hepatitis C, ChronicLocation: Bronx, NY
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-11030
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-11030
Conditions: Hepatitis C, ChronicLocation: Manhasset, NY
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-17033
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-17033
Conditions: Hepatitis C, ChronicLocation: Hershey, PA
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-21093
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-21093
Conditions: Hepatitis C, ChronicLocation: Baltimore, MD
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-23602
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-23602
Conditions: Hepatitis C, ChronicLocation: Newport News, VA
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-27599
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-27599
Conditions: Hepatitis C, ChronicLocation: Chapel Hill, NC
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-28304
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-28304
Conditions: Hepatitis C, ChronicLocation: Fayetteville, NC
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-30033
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-30033
Conditions: Hepatitis C, ChronicLocation: Decatur, GA
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-32804
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-32804
Conditions: Hepatitis C, ChronicLocation: Orlando, FL
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-32809
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-32809
Conditions: Hepatitis C, ChronicLocation: Orlando, FL
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-33143
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-33143
Conditions: Hepatitis C, ChronicLocation: South Miami, FL
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-37211
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-37211
Conditions: Hepatitis C, ChronicLocation: Nashville, TN
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-48202
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-48202
Conditions: Hepatitis C, ChronicLocation: Detroit, MI
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-60637
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-60637
Conditions: Hepatitis C, ChronicLocation: Chicago, IL
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-70112
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-70112
Conditions: Hepatitis C, ChronicLocation: New Orleans, LA
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-77030
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-77030
Conditions: Hepatitis C, ChronicLocation: Houston, TX
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-78215
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-78215
Conditions: Hepatitis C, ChronicLocation: San Antonio, TX
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-78234
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-78234
Conditions: Hepatitis C, ChronicLocation: Fort Sam Houston, TX
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-80045
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-80045
Conditions: Hepatitis C, ChronicLocation: Aurora, CO
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-92037
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-92037
Conditions: Hepatitis C, ChronicLocation: La Jolla, CA
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-92123
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-92123
Conditions: Hepatitis C, ChronicLocation: San Diego, CA
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-92154
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-92154
Conditions: Hepatitis C, ChronicLocation: San Diego, CA
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-94143
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-94143
Conditions: Hepatitis C, ChronicLocation: San Francisco, CA
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-95817
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-95817
Conditions: Hepatitis C, ChronicLocation: Sacramento, CA
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-96817
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-96817
Conditions: Hepatitis C, ChronicLocation: Honolulu, HI
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-97504
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-97504
Conditions: Hepatitis C, ChronicLocation: Medford, OR
A Study of Early Immunologic Response in Asian Patients With Chronic Hepatitis B, Treated With Pegasys (Peginterferon Alfa-2a (40KD)), Nucleoside Analogues, or Both - NCT00962871-94143
A Study of Early Immunologic Response in Asian Patients With Chronic Hepatitis B, Treated With Pegasys (Peginterferon Alfa-2a (40KD)), Nucleoside Analogues, or Both - NCT00962871-94143
Conditions: Hepatitis B, ChronicLocation: San Francisco, CA
A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-02115
A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-02115
Conditions: Hepatitis B, ChronicLocation: Boston, MA
A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-02903
A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-02903
Conditions: Hepatitis B, ChronicLocation: Providence, RI
A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-06106
A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-06106
Conditions: Hepatitis B, ChronicLocation: Hartford, CT
A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-10029
A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-10029
Conditions: Hepatitis B, ChronicLocation: New York, NY
A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-19104
A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-19104
Conditions: Hepatitis B, ChronicLocation: Philadelphia, PA
A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-21287
A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-21287
Conditions: Hepatitis B, ChronicLocation: Baltimore, MD
A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-32610
A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-32610
Conditions: Hepatitis B, ChronicLocation: Gainesville, FL
A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-75390
A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-75390
Conditions: Hepatitis B, ChronicLocation: Dallas, TX
A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-94143
A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-94143
Conditions: Hepatitis B, ChronicLocation: San Francisco, CA
A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area - NCT00913757-
A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area - NCT00913757-
Conditions: Carcinoma, Hepatocellular - Liver Cirrhosis, Alcoholic - Hepatitis, Alcoholic - Hepatitis, Chronic - Hepatitis, Viral, HumanLocation: Baltimore, MD
A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area - NCT00913757-20892
A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area - NCT00913757-20892
Conditions: Carcinoma, Hepatocellular - Liver Cirrhosis, Alcoholic - Hepatitis, Alcoholic - Hepatitis, Chronic - Hepatitis, Viral, HumanLocation: Bethesda, MD
A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area - NCT00913757-21205
A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area - NCT00913757-21205
Conditions: Carcinoma, Hepatocellular - Liver Cirrhosis, Alcoholic - Hepatitis, Alcoholic - Hepatitis, Chronic - Hepatitis, Viral, HumanLocation: Baltimore, MD
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-02905
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-02905
Conditions: Hepatitis C, ChronicLocation: Providence, RI
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-10021
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-10021
Conditions: Hepatitis C, ChronicLocation: New York, NY
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-11030
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-11030
Conditions: Hepatitis C, ChronicLocation: Manhasset, NY
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-21093
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-21093
Conditions: Hepatitis C, ChronicLocation: Lutherville, MD
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-23249
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-23249
Conditions: Hepatitis C, ChronicLocation: Richmond, VA
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-27599
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-27599
Conditions: Hepatitis C, ChronicLocation: Chapel Hill, NC
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-37211
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-37211
Conditions: Hepatitis C, ChronicLocation: Nashville, TN
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-78215
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-78215
Conditions: Hepatitis C, ChronicLocation: San Antonio, TX
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-84132
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-84132
Conditions: Hepatitis C, ChronicLocation: Salt Lake City, UT
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-92118
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-92118
Conditions: Hepatitis C, ChronicLocation: Coronado, CA
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-94115
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-94115
Conditions: Hepatitis C, ChronicLocation: San Francisco, CA
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-95817
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-95817
Conditions: Hepatitis C, ChronicLocation: Sacramento, CA
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-97239
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-97239
Conditions: Hepatitis C, ChronicLocation: Portland, OR
A Study of Pegasys Monotherapy in Patients With Chronic Hepatitis B Who Have Participated in Previous Studies - NCT00962975-94143
A Study of Pegasys Monotherapy in Patients With Chronic Hepatitis B Who Have Participated in Previous Studies - NCT00962975-94143
Conditions: Hepatitis B, ChronicLocation: San Francisco, CA
A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01225380-02115
A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01225380-02115
Conditions: Chronic Hepatitis C InfectionLocation: Boston, MA
A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01225380-11030
A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01225380-11030
Conditions: Chronic Hepatitis C InfectionLocation: Manhasset, NY
A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01225380-44106
A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01225380-44106
Conditions: Chronic Hepatitis C InfectionLocation: Cleveland, OH
A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01225380-76012
A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01225380-76012
Conditions: Chronic Hepatitis C InfectionLocation: Arlington, TX
A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01225380-92123
A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01225380-92123
Conditions: Chronic Hepatitis C InfectionLocation: San Diego, CA
A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01225380-94115
A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01225380-94115
Conditions: Chronic Hepatitis C InfectionLocation: San Francisco, CA
A Study of Vaniprevir (MK7009) in Patients With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies - NCT00943761-14642
A Study of Vaniprevir (MK7009) in Patients With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies - NCT00943761-14642
Conditions: Chronic Hepatitis C Infection (HCV)Location: Rochester, NY
A Study of Vaniprevir (MK7009) in Patients With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies - NCT00943761-21201
A Study of Vaniprevir (MK7009) in Patients With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies - NCT00943761-21201
Conditions: Chronic Hepatitis C Infection (HCV)Location: Baltimore, MD
A Study of Vaniprevir (MK7009) in Patients With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies - NCT00943761-28203
A Study of Vaniprevir (MK7009) in Patients With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies - NCT00943761-28203
Conditions: Chronic Hepatitis C Infection (HCV)Location: Charlotte, NC
A Study of Vaniprevir (MK7009) in Patients With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies - NCT00943761-70808
A Study of Vaniprevir (MK7009) in Patients With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies - NCT00943761-70808
Conditions: Chronic Hepatitis C Infection (HCV)Location: Baton Rouge, LA
A Study of Vaniprevir (MK7009) in Patients With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies - NCT00943761-78215Conditions: Chronic Hepatitis C Infection (HCV)Location: San Antonio, TX
A Study of Vaniprevir (MK7009) in Patients With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies - NCT00943761-98103
A Study of Vaniprevir (MK7009) in Patients With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies - NCT00943761-78215Conditions: Chronic Hepatitis C Infection (HCV)Location: San Antonio, TX
A Study of Vaniprevir (MK7009) in Patients With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies - NCT00943761-98103
Conditions: Chronic Hepatitis C Infection (HCV)Location: Seattle, WA
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV) - NCT01221298-78215
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV) - NCT01221298-78215
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: San Antonio, TX
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV) - NCT01221298-90211
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV) - NCT01221298-90211
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Beverly Hills, CA
Acoustic Liver Biopsy in Normals and in Patients With Cirrhosis Using Endoscopic Ultrasound - NCT01208311-19140
Acoustic Liver Biopsy in Normals and in Patients With Cirrhosis Using Endoscopic Ultrasound - NCT01208311-19140
Conditions: Normal - Alcoholism - Cirrhosis - Hepatitis CLocation: Philadelphia, PA
An Integrated Care Model for Improving HCV Patient Outcomes IIR-07-101-3 - NCT00722423-10468
An Integrated Care Model for Improving HCV Patient Outcomes IIR-07-101-3 - NCT00722423-10468
Conditions: Hepatitis CLocation: Bronx, NY
An Integrated Care Model for Improving HCV Patient Outcomes IIR-07-101-3 - NCT00722423-92161
An Integrated Care Model for Improving HCV Patient Outcomes IIR-07-101-3 - NCT00722423-92161
Conditions: Hepatitis CLocation: San Diego, CA
An Integrated Care Model for Improving HCV Patient Outcomes IIR-07-101-3 - NCT00722423-94304
An Integrated Care Model for Improving HCV Patient Outcomes IIR-07-101-3 - NCT00722423-94304
Conditions: Hepatitis CLocation: Palo Alto, CA
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-02905
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-02905
Conditions: Hepatitis C, ChronicLocation: Providence, RI
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-07102
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-07102
Conditions: Hepatitis C, ChronicLocation: Newark, NJ
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-10021
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-10021
Conditions: Hepatitis C, ChronicLocation: New York, NY
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-21093
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-21093
Conditions: Hepatitis C, ChronicLocation: Lutherville, MD
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-23249
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-23249
Conditions: Hepatitis C, ChronicLocation: Richmond, VA
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-29204
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-29204
Conditions: Hepatitis C, ChronicLocation: Columbia, SC
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-30060
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-30060
Conditions: Hepatitis C, ChronicLocation: Marietta, GA
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-32610
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-32610
Conditions: Hepatitis C, ChronicLocation: Gainesville, FL
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-34243
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-34243
Conditions: Hepatitis C, ChronicLocation: Sarasota, FL
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-35294
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-35294
Conditions: Hepatitis C, ChronicLocation: Birmingham, AL
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-37211
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-37211
Conditions: Hepatitis C, ChronicLocation: Nashville, TN
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-60637
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-60637
Conditions: Hepatitis C, ChronicLocation: Chicago, IL
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-64131
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-64131
Conditions: Hepatitis C, ChronicLocation: Kansas City, MO
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-77030
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-77030
Conditions: Hepatitis C, ChronicLocation: Houston, TX
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-78234
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-78234
Conditions: Hepatitis C, ChronicLocation: Fort Sam Houston, TX
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-80045
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-80045
Conditions: Hepatitis C, ChronicLocation: Aurora, CO
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-92037
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-92037
Conditions: Hepatitis C, ChronicLocation: La Jolla, CA
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-92154
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-92154
Conditions: Hepatitis C, ChronicLocation: San Diego, CA
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-94115
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-94115
Conditions: Hepatitis C, ChronicLocation: San Francisco, CA
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-95817
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-95817
Conditions: Hepatitis C, ChronicLocation: Sacramento, CA
Angiotensin Receptor Blockade as an Anti-Fibrotic Intervention in Patients With Chronic Hepatitis C - NCT00930995-95661
Angiotensin Receptor Blockade as an Anti-Fibrotic Intervention in Patients With Chronic Hepatitis C - NCT00930995-95661
Conditions: Hepatitis CLocation: Roseville, CA
Angiotensin Receptor Blockade as an Anti-Fibrotic Intervention in Patients With Chronic Hepatitis C - NCT00930995-95825
Angiotensin Receptor Blockade as an Anti-Fibrotic Intervention in Patients With Chronic Hepatitis C - NCT00930995-95825
Conditions: Hepatitis CLocation: Sacramento, CA
Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection - NCT00239733-10021
Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection - NCT00239733-10021
Conditions: Thrombocytopenia - Hepatitis C - HIV InfectionsLocation: New York, NY
Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis - NCT00854087-77030
Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis - NCT00854087-77030
Conditions: Chronic Hepatitis C InfectionLocation: Houston, TX
Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis - NCT00854087-84132
Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis - NCT00854087-84132
Conditions: Chronic Hepatitis C InfectionLocation: Salt Lake City, UT
Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis - NCT00854087-91105
Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis - NCT00854087-91105
Conditions: Chronic Hepatitis C InfectionLocation: Pasadena, CA
Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis - NCT00854087-92118
Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis - NCT00854087-92118
Conditions: Chronic Hepatitis C InfectionLocation: Coronado, CA
Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis - NCT00854087-92673
Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis - NCT00854087-92673
Conditions: Chronic Hepatitis C InfectionLocation: San Clemente, CA
Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis - NCT00854087-95817
Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis - NCT00854087-95817
Conditions: Chronic Hepatitis C InfectionLocation: Sacramento, CA
Baclofen to Reduce Alcohol Use in Veterans With HCV - NCT01008280-55417
Baclofen to Reduce Alcohol Use in Veterans With HCV - NCT01008280-55417
Conditions: Hepatitis C - Alcohol Use DisordersLocation: Minneapolis, MN
Baclofen to Reduce Alcohol Use in Veterans With HCV - NCT01008280-90822
Baclofen to Reduce Alcohol Use in Veterans With HCV - NCT01008280-90822
Conditions: Hepatitis C - Alcohol Use DisordersLocation: Long Beach, CA
Baclofen to Reduce Alcohol Use in Veterans With HCV - NCT01008280-97201
Baclofen to Reduce Alcohol Use in Veterans With HCV - NCT01008280-97201
Conditions: Hepatitis C - Alcohol Use DisordersLocation: Portland, OR
Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus - NCT00503347-07102
Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus - NCT00503347-07102
Conditions: Hepatitis C Virus - HIV InfectionsLocation: Newark, NJ
Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus - NCT00503347-21287
Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus - NCT00503347-21287
Conditions: Hepatitis C Virus - HIV InfectionsLocation: Baltimore, MD
Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus - NCT00503347-30308
Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus - NCT00503347-30308
Conditions: Hepatitis C Virus - HIV InfectionsLocation: Atlanta, GA
Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus - NCT00503347-75204
Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus - NCT00503347-75204
Conditions: Hepatitis C Virus - HIV InfectionsLocation: Dallas, TX
Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus - NCT00503347-90036
Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus - NCT00503347-90036
Conditions: Hepatitis C Virus - HIV InfectionsLocation: Los Angeles, CA
Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus - NCT00503347-92663
Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus - NCT00503347-92663
Conditions: Hepatitis C Virus - HIV InfectionsLocation: Newport Beach, CA
Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy - NCT00747539-90024
Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy - NCT00747539-90024
Conditions: HIV - Hepatitis C - InfectionsLocation: Los Angeles, CA
Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy - NCT00747539-90028
Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy - NCT00747539-90028
Conditions: HIV - Hepatitis C - InfectionsLocation: Los Angeles, CA
Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy - NCT00747539-90073
Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy - NCT00747539-90073
Conditions: HIV - Hepatitis C - InfectionsLocation: Los Angeles, CA
Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy - NCT00747539-93534
Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy - NCT00747539-93534
Conditions: HIV - Hepatitis C - InfectionsLocation: Lancaster, CA
Brief Intervention for Drug Misuse in the Emergency Department - NCT01124591-02903
Brief Intervention for Drug Misuse in the Emergency Department - NCT01124591-02903
Conditions: Substance Abuse Detection - HIV - Hepatitis B - Hepatitis C - Brief Intervention - HIV InfectionsLocation: Providence, RI
Cell Bound Complement Activation Proteins as Markers of Liver Injury - NCT01025531-15213
Cell Bound Complement Activation Proteins as Markers of Liver Injury - NCT01025531-15213
Conditions: Hepatitis CLocation: Pittsburgh, PA
Cerebral Effects of Pegylated Interferon in Hepatitis C Positive Subjects - NCT00136214-02215
Cerebral Effects of Pegylated Interferon in Hepatitis C Positive Subjects - NCT00136214-02215
Conditions: Hepatitis CLocation: Boston, MA
Characterization of Clonal B Cell Populations in HCV Infection - NCT00435201-10065
Characterization of Clonal B Cell Populations in HCV Infection - NCT00435201-10065
Conditions: Hepatitis CLocation: New York, NY
Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390 - NCT00996216-06520
Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390 - NCT00996216-06520
Conditions: Hepatitis C - ThrombocytopaeniaLocation: New Haven, CT
Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390 - NCT00996216-37212
Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390 - NCT00996216-37212
Conditions: Hepatitis C - ThrombocytopaeniaLocation: Nashville, TN
Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390 - NCT00996216-96817
Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390 - NCT00996216-96817
Conditions: Hepatitis C - ThrombocytopaeniaLocation: Honolulu, HI
Comparative Effectiveness of Web-based Versus Traditional Adolescent HIV Prevention - NCT01142882-10461
Comparative Effectiveness of Web-based Versus Traditional Adolescent HIV Prevention - NCT01142882-10461
Conditions: HIV Infections - Hepatitis - Sexually Transmitted InfectionsLocation: Bronx, NY
Comparative Effectiveness of Web-based Versus Traditional Adolescent HIV Prevention - NCT01142882-11217Conditions: HIV Infections - Hepatitis - Sexually Transmitted InfectionsLocation: Brooklyn, NY
Computer-Assisted Tailored Cue-card Health [CATCH] Study - NCT01170741-27601Conditions: Human Immunodeficiency Virus - STDs - Hepatitis, Viral, HumanLocation: Raleigh, NC
Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection - NCT01097395-80045Conditions: Hepatitis C VirusLocation: Aurora, CO
Comparative Effectiveness of Web-based Versus Traditional Adolescent HIV Prevention - NCT01142882-11217Conditions: HIV Infections - Hepatitis - Sexually Transmitted InfectionsLocation: Brooklyn, NY
Computer-Assisted Tailored Cue-card Health [CATCH] Study - NCT01170741-27601Conditions: Human Immunodeficiency Virus - STDs - Hepatitis, Viral, HumanLocation: Raleigh, NC
Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection - NCT01097395-80045Conditions: Hepatitis C VirusLocation: Aurora, CO
No comments:
Post a Comment